BeOne Medicines (BEIGF) Receivables - Other (2017 - 2023)

BeOne Medicines (BEIGF) has 7 years of Receivables - Other data on file, last reported at $1.7 million in Q4 2023.

• Receivables - Other for Q4 2023 came in at $1.7 million, down 42.91% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.7 million (down 42.91% YoY), and the FY2023 annual result was $1.7 million, down 42.91% from the prior year.
• Receivables - Other climbed to $1.7 million in Q4 2023 per BEIGF's latest filing, from $1.6 million in the prior quarter.
• Over five years, Receivables - Other peaked at $7.2 million in Q3 2021 and troughed at $1.3 million in Q1 2023.
• A 5-year average of $4.0 million and a median of $3.4 million in 2019 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2020 and 2023: Receivables - Other soared 235.96% in 2020, then slumped 74.81% in 2023.
• A 5-year view of Receivables - Other shows it stood at $1.7 million in 2019, then jumped by 283.93% to $6.6 million in 2020, then slipped by 23.67% to $5.1 million in 2021, then slumped by 39.85% to $3.0 million in 2022, then plunged by 42.91% to $1.7 million in 2023.
• Business Quant data shows BEIGF's Receivables - Other at $1.7 million in Q4 2023, $1.6 million in Q3 2023, and $2.0 million in Q2 2023.